BOSTON, March 2, 2021 /PRNewswire/ -- Stealth
BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of novel therapies for diseases involving mitochondrial
dysfunction, today announced that Reenie
McCarthy, CEO, will present at the following upcoming
virtual investor conferences in March:
H.C. Wainwright Global Life Sciences Conference
Date:
Tuesday, March 9, 2021
Time: 7:00 a.m. ET
Oppenheimer's 31st Annual Healthcare Conference
Date:
Wednesday, March 17, 2021
Time: 10:40 am ET
A live audio webcast of the presentations will be available on
the Investors & News section of Stealth's website
at https://investor.stealthbt.com/. A replay of the webcasts
will be archived on Stealth's website for 30 days following the
event.
About Stealth
We are a clinical-stage biotechnology
company focused on the discovery, development, and
commercialization of novel therapies for diseases involving
mitochondrial dysfunction. Mitochondria, found in nearly every cell
in the body, are the body's main source of energy production and
are critical for normal organ function. Dysfunctional mitochondria
characterize a number of rare genetic diseases and are involved in
many common age-related diseases, typically involving organ systems
with high energy demands such as the heart, the eye, and the brain.
We believe our lead product candidate, elamipretide, has the
potential to treat both rare metabolic cardiomyopathies, such as
Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare
mitochondrial diseases entailing nuclear DNA mutations, such as
POLG-related disorders, as well as ophthalmic diseases entailing
mitochondrial dysfunction, such as dry AMD and Leber's hereditary
optic neuropathy. We are evaluating our second-generation
clinical-stage candidate, SBT-272, and our new series of small
molecules, SBT-550, for rare neurological disease indications
following promising preclinical data. We have optimized our
discovery platform to identify novel mitochondria-targeted
compounds which may be nominated as therapeutic product candidates
or utilized as scaffolds to deliver other compounds to
mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march-301238949.html
SOURCE Stealth BioTherapeutics Inc.